|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
49,160,000 |
Market
Cap: |
354.94(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$2.14 - $13.81 |
|
Level
I Sector: |
Financials |
Level
II Sector: |
Financial Services |
Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
300 |
31,500 |
Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
1 |
6 |
Total Shares Sold |
0 |
0 |
0 |
155,302 |
Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
Total People Sold |
0 |
0 |
0 |
5 |
Total Sell Transactions |
0 |
0 |
0 |
9 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Novartis Ag |
10% Owner |
|
2018-02-15 |
4 |
A |
$0.00 |
$0 |
I/I |
67,925 |
2,872,013 |
|
- |
|
Truffle Capital S.a.s. |
10% Owner |
|
2018-02-15 |
4 |
A |
$0.00 |
$0 |
I/I |
14,943 |
76,700 |
|
- |
|
Novartis Ag |
10% Owner |
|
2018-02-13 |
4 |
A |
$0.00 |
$0 |
I/I |
269,527 |
2,804,088 |
|
- |
|
Truffle Capital S.a.s. |
10% Owner |
|
2018-02-13 |
4 |
A |
$0.00 |
$0 |
I/I |
59,297 |
72,217 |
|
- |
|
Truffle Capital S.a.s. |
10% Owner |
|
2018-01-17 |
4 |
A |
$0.00 |
$0 |
I/I |
38,851 |
54,428 |
|
- |
|
Novartis Ag |
10% Owner |
|
2018-01-17 |
4 |
A |
$0.00 |
$0 |
I/I |
176,586 |
2,534,561 |
|
- |
|
Enright William |
President and CEO |
|
2018-01-02 |
4 |
OE |
$0.08 |
$14,668 |
D/D |
183,347 |
364,511 |
|
- |
|
Sayare Mitchel |
Director |
|
2017-12-29 |
4 |
B |
$1.95 |
$9,963 |
I/I |
5,100 |
32,650 |
2.1 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-29 |
4 |
B |
$1.93 |
$74,778 |
D/D |
38,699 |
589,453 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-28 |
4 |
B |
$1.92 |
$112,672 |
D/D |
58,711 |
550,754 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-27 |
4 |
B |
$1.76 |
$137,210 |
D/D |
77,706 |
492,043 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-26 |
4 |
B |
$1.81 |
$93,269 |
D/D |
51,442 |
414,337 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-22 |
4 |
B |
$1.61 |
$28,877 |
D/D |
17,982 |
362,895 |
2.39 |
- |
|
Novartis Ag |
10% Owner |
|
2017-12-15 |
4 |
A |
$0.00 |
$0 |
I/I |
65,718 |
2,357,975 |
|
- |
|
Truffle Capital S.a.s. |
10% Owner |
|
2017-12-15 |
4 |
A |
$0.00 |
$0 |
I/I |
14,458 |
42,773 |
|
- |
|
Novartis Ag |
10% Owner |
|
2017-12-13 |
4 |
A |
$0.00 |
$0 |
I/I |
242,694 |
2,292,257 |
|
- |
|
Truffle Capital S.a.s. |
10% Owner |
|
2017-12-13 |
4 |
A |
$0.00 |
$0 |
I/I |
53,393 |
38,436 |
|
- |
|
Schaffer Derace L |
Director |
|
2017-12-07 |
4 |
B |
$1.74 |
$13,308 |
D/D |
7,639 |
344,913 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-06 |
4 |
B |
$1.80 |
$28,996 |
D/D |
16,106 |
337,274 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-05 |
4 |
B |
$1.78 |
$23,987 |
D/D |
13,495 |
321,168 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-04 |
4 |
B |
$1.81 |
$13,195 |
D/D |
7,300 |
307,673 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-12-01 |
4 |
B |
$1.80 |
$9,405 |
D/D |
5,215 |
300,373 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-11-30 |
4 |
B |
$1.84 |
$23,816 |
D/D |
12,978 |
295,158 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-11-29 |
4 |
B |
$1.94 |
$15,377 |
D/D |
7,942 |
282,180 |
2.39 |
- |
|
Schaffer Derace L |
Director |
|
2017-11-28 |
4 |
B |
$1.97 |
$24,445 |
D/D |
12,395 |
274,238 |
2.39 |
- |
|
260 Records found
|
|
Page 8 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|